N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: Insights from the aristotle trial (apixaban for the prevention of stroke in subjects with atrial fibrillation)

Journal of the American College of Cardiology

Volumn 61, Issue 22, 2013, Pages 2274-2284

  Hijazi, Ziad ^a   Wallentin, Lars ^a   Siegbahn, Agneta ^a   Andersson, Ulrika ^a   Christersson, Christina ^a   Ezekowitz, Justin ^b   Gersh, Bernard J ^c   Hanna, Michael ^d   Hohnloser, Stefan ^e   Horowitz, John ^f   Huber, Kurt ^g   Hylek, Elaine M ^h   Lopes, Renato D ⁱ   McMurray, John J V ^j   Granger, Christopher B ⁱ  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MAYO CLINIC   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e GOETHE UNIVERSITY   (Germany)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g WILHELMINEN HOSPITAL   (Austria)

^h BOSTON UNIVERSITY MEDICAL CENTER   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j WESTERN INFIRMARY   (United Kingdom)

more..

Author keywords

atrial fibrillation; natriuretic peptides; NT proBNP; risk assessment

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APIXABAN; WARFARIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHA2DS2VASC SCORE; DRUG EFFICACY; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; EMBOLISM; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; STROKE; WARFARIN;

EID: 84878314042     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.11.082     Document Type: Article

References (36)

1. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, H. Silbershatz, W.B. Kannel, and D. Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 1998 946 952
2. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
3. A.J. Camm, P. Kirchhof, and G.Y. Lip Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
4. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
5. F. Boomsma, and A.H. van den Meiracker Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use Cardiovasc Res 51 2001 442 449
6. L.B. Daniels, and A.S. Maisel Natriuretic peptides J Am Coll Cardiol 50 2007 2357 2368
7. M.M. Redfield, R.J. Rodeheffer, S.J. Jacobsen, D.W. Mahoney, K.R. Bailey, and J.C. Burnett Jr. Plasma brain natriuretic peptide concentration: impact of age and gender J Am Coll Cardiol 40 2002 976 982
8. N. Arakawa, M. Nakamura, H. Aoki, and K. Hiramori Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction J Am Coll Cardiol 27 1996 1656 1661
9. J.A. de Lemos, D.A. Morrow, and J.H. Bentley The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes N Engl J Med 345 2001 1014 1021
10. G.C. Fonarow, W.F. Peacock, C.O. Phillips, M.M. Givertz, and M. Lopatin Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure J Am Coll Cardiol 49 2007 1943 1950
11. Z. Hijazi, J. Oldgren, and U. Andersson Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) substudy Circulation 125 2012 1605 1616
12. S.K. James, B. Lindahl, and A. Siegbahn N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy Circulation 108 2003 275 281
13. C. Kragelund, B. Gronning, L. Kober, P. Hildebrandt, and R. Steffensen N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease N Engl J Med 352 2005 666 675
14. T. Tsutamoto, A. Wada, and K. Maeda Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction Circulation 96 1997 509 516
15. T.J. Wang, M.G. Larson, and D. Levy Plasma natriuretic peptide levels and the risk of cardiovascular events and death N Engl J Med 350 2004 655 663
16. R.D. Lopes, J.H. Alexander, and S.M. Al-Khatib Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 2010 331 339
17. N. Johnston, T. Jernberg, and B. Lindahl Biochemical indicators of cardiac and renal function in a healthy elderly population Clin Biochem 37 2004 210 216
18. K.T. Yeo, A.H. Wu, and F.S. Apple Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay Clin Chim Acta 338 2003 107 115
19. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845
20. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172 discussion 207-12
21. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Comments on 'Integrated discrimination and net reclassification improvements - practical advice' Stat Med 27 2008 207 212
22. L. Friberg, M. Rosenqvist, and G.Y. Lip Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study Eur Heart J 33 2012 1500 1510
23. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
24. C.B. Granger, J.H. Alexander, and J.J. McMurray Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
25. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey Chest 138 2010 1093 1100
26. H. Silvet, Y. Young-Xu, D. Walleigh, and S. Ravid Brain natriuretic peptide is elevated in outpatients with atrial fibrillation Am J Cardiol 92 2003 1124 1127
27. P.T. Ellinor, A.F. Low, K.K. Patton, M.A. Shea, and C.A. Macrae Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation J Am Coll Cardiol 45 2005 82 86
28. R.J. Shelton, A.L. Clark, K. Goode, A.S. Rigby, and J.G. Cleland The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation Eur Heart J 27 2006 2353 2361
29. M.K. Freynhofer, R. Jarai, and T. Hochtl Predictive value of plasma Nt-proBNP and body mass index for recurrence of atrial fibrillation after cardioversion Int J Cardiol 149 2011 257 259
30. P. Jourdain, M. Bellorini, and F. Funck Short-term effects of sinus rhythm restoration in patients with lone atrial fibrillation: a hormonal study Eur J Heart Fail 4 2002 263 267
31. B. Wozakowska-Kaplon Effect of sinus rhythm restoration on plasma brain natriuretic peptide in patients with atrial fibrillation Am J Cardiol 93 2004 1555 1558
32. T. Yamada, Y. Murakami, and T. Okada Plasma atrial natriuretic peptide and brain natriuretic peptide levels after radiofrequency catheter ablation of atrial fibrillation Am J Cardiol 97 2006 1741 1744
33. J.P. Goetze, L. Friis-Hansen, J.F. Rehfeld, B. Nilsson, and J.H. Svendsen Atrial secretion of B-type natriuretic peptide Eur Heart J 27 2006 1648 1650
34. S. Inoue, Y. Murakami, K. Sano, H. Katoh, and T. Shimada Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation J Card Fail 6 2000 92 96
35. H. Yasue, M. Yoshimura, and H. Sumida Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure Circulation 90 1994 195 203
36. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography Ann Intern Med 128 1998 639 647